Apnimed Successfully Completes Phase 1 Study in Lead Program for Obstructive Sleep Apnea

Apnimed\, a clinical-stage pharmaceutical company focused on developing medicines to treat sleep apnea and related disorders\, today announced the results of a Phase 1 study for a component of the company’s lead combination drug candidate\, AD109\, which i